In male Sprague Dawley rats, GSK1059865 at 5 mg/kg i.p. did not significantly alter recorded sleep parameters compared with vehicle. In male Sprague–Dawley rats, subcutaneous GSK1059865 at 10 mg/kg with vehicle produced a lower NREM bout number than vehicle with vehicle. In male wild-type mice, GSK1059865 significantly attenuated MK-801-elicited cortical glutamate release compared with vehicle-treated mice. In male Sprague-Dawley rats, GSK1059865 significantly decreased expression of the cocaine CPP response compared with Vehicle-Cocaine + Vehicle on test day. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
total sleep time (TST) in Male Sprague Dawley rats (275–300 g, Charles River Italy)
Animal study · Male Sprague Dawley rats (275–300 g, Charles River Italy) [1]
Model: Male Sprague Dawley rats (275–300 g, Charles River Italy). Treatment: 5 mg/kg i.p.. Result: At a lower dose (5 mg/kg i.p.) the compound did not significantly alter any of the sleep parameters recorded.
Conditions shared by the study groups
- Route
- i.p.
- Treatment course
- six hours into the dark phase (Circadian time (CT) 18); 5-hour test period
- GSK1059865 5 mg/kg i.p.
- Model: Male Sprague Dawley rats (275–300 g, Charles River Italy)
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: GSK1059865
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > OX2R but not OX1R antagonism produces robust sleep-promoting effects (S33); Methods > Sleep recording and analysis (S113, S124, S126, S128); Figure 6 legend (S168)
total sleep time (TST): total sleep time (TST); comparator: vehicle — Results > OX2R but not OX1R antagonism produces robust sleep-promoting effects (S33); Methods > Sleep recording and analysis (S124)
GSK1059865 5 mg/kg i.p. · Results > OX2R but not OX1R antagonism produces robust sleep-promoting effects (S33); Methods > Sleep recording and analysis (S126, S128)
NREM bout number in male rats
Animal study · male Sprague–Dawley rats; n = 7 animals [2]
NREM bout number, 6-h period following the treatment: GSK-1059865 (10 mg/kg) + Vehicle, 70.7±3.7; Vehicle + Vehicle, 82.7±2.6 (*P < 0.05 vs. Vehicle + Vehicle).
Conditions shared by the study groups
- Route
- subcutaneous (sc) route
- Treatment course
- at the onset of the dark phase; 6-h period following the treatment
- Vehicle
- 5% pharmasolve, 20% solutol, 75% hydroxypropyl-β-cyclodextrin (20% w/v)
- GSK1059865 10 mg/kg
- Model: male Sprague–Dawley rats; n = 7 animals
Methods and source locations
Compound reported in the paper: GSK1059865
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Animals (S1); Materials and methods > Drugs and experimental design (S13, S14); Results > Disinhibition of REM sleep by additional pharmacological blockade of OX1R to OX2R antagonism (S45); Table 2 legend (S70, S71); Table 2 (T2.h1, T2.r1, T2.r2)
NREM bout number: NREM bout number; comparator: Vehicle + Vehicle — Table 2 legend (S70, S71); Table 2 (T2.h1, T2.r1, T2.r2)
GSK1059865 10 mg/kg · Materials and methods > Drugs and experimental design (S13); Results > Disinhibition of REM sleep by additional pharmacological blockade of OX1R to OX2R antagonism (S45); Table 2 legend (S70, S71); Table 2 (T2.h1, T2.r1, T2.r2)
Cortical glutamate release in wild-type mice
Animal study · Male wild-type mice [3]
Model: Male wild-type mice. Treatment: 10 mg/kg. Result: In wild-type mice, GSK-1059865 (10 mg/kg, S.C.) significantly attenuated cortical glutamate release elicited by MK-801 (0.178 mg/kg S.C.) (Figure 1A, treatment group: F = 5.537, df = 1, p = 0.037; block: F = 3.677, df = 2, p = 0.057)..
Conditions shared by the study groups
- Route
- S.C.
- Treatment course
- 30 min prior to the injection of MK-801
- Vehicle
- 30% sulfobutylether(7)-β-cyclodextrin (SBE) or 5% Pharmasolve, 20% Cremaphor and 75% D5W
- GSK1059865 10 mg/kg
- Model: Male wild-type mice
Methods and source locations
Compound reported in the paper: GSK1059865
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods (S2, S4, S5, S20, S23, S28, S29); Results (S40)
area under the curve of the baseline change in glutamate release over 1 h post MK-801 stimulation: area under the curve of the baseline change in glutamate release over 1 h post MK-801 stimulation; comparator: vehicle treated mice — Methods (S28); Results (S40)
GSK1059865 10 mg/kg · Methods (S20); Results (S40)
raw time spent in each chamber in Male Sprague-Dawley rats (155–165 g upon arrival, Charles River, Como, Italy); n = 10 each
Animal study · Male Sprague-Dawley rats (155–165 g upon arrival, Charles River, Como, Italy); n = 10 each [1]
Model: Male Sprague-Dawley rats (155–165 g upon arrival, Charles River, Como, Italy); n = 10 each. Treatment: 10 or 30 mg/kg i.p. Result: significantly decreased the expression of the CPP response to cocaine compared to vehicle at 10 mg/kg and 30 mg/kg i.p. (** p<0.01 vs. Vehicle; ANOVA and Student-Newman-Keuls test).
Conditions shared by the study groups
- Route
- i.p.
- Treatment course
- 30 minutes prior to the behavioural test
- GSK1059865 10 or 30 mg/kg i.p
- Model: Male Sprague-Dawley rats (155–165 g upon arrival, Charles River, Como, Italy); n = 10 each
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: GSK1059865
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Pharmacokinetics and bioanalysis (S53); Methods > Sleep recording and analysis (S126); Methods > Conditioned place –preference (CPP) (S131, S141, S142, S144, S149, S150, S151, S152); Figure 7 legend (S174, S176)
raw time spent in each chamber: raw time spent in each chamber; comparator: Vehicle-Cocaine + Vehicle on test day — Methods > Conditioned place –preference (CPP) (S152); Figure 7 legend (S174)
GSK1059865 10 or 30 mg/kg i.p · Methods > Conditioned place –preference (CPP) (S144); Figure 7 legend (S174)